Biotech startup Ariadne is testing a psychedelic-like drug against apathy in Parkinson's disease, according to STAT's Readout newsletter. The brief names apathy as the target symptom but gives no details on the compound, trial design, or timeline.
The item appeared in STAT's September 17 biotech roundup, which also covered research involving mice with half-human brains. Ariadne's announcement is the only mention of the Parkinson's program, and no efficacy or safety data were reported.
Because the report comes from a single newsletter brief, there are no conflicting sources to compare. The main takeaway is that Ariadne is entering this specific Parkinson's symptom space, with further details expected from the company or future trials.